Marshall Wace North America’s Anixa Biosciences ANIX Stock Holding History

Marshall Wace North America’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3	Closed	–	–	1129
2019 Q1	$0	Buy	+3	New	+$14	﹤0.01%	1541

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace North America's ANIX Position: Q2 2019 in Review

Marshall Wace North America sold out of Anixa Biosciences (ANIX) in Q2 2019, closing a stake of 3 shares.

Marshall Wace North America first reported a position in ANIX in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 16 funds tracked by Wall St. Rank hold ANIX as of Q2 2019.

Marshall Wace North America reported no remaining Anixa Biosciences position as of Q2 2019 after selling out during the quarter.
Marshall Wace North America sold 3 Anixa Biosciences shares in Q2 2019.
Marshall Wace North America first reported a position in Anixa Biosciences in Q1 2019 and held it in 1 quarter.
Marshall Wace North America's Anixa Biosciences position peaked at $0 in Q1 2019.
16 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.